TCGA-A2-A0EP-01A-52R-A22U-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 120
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.620
- ALLOGRAFT_REJECTION+0.600
- INFLAMMATORY_RESPONSE+0.580
- TNFA_SIGNALING_VIA_NFKB+0.580
- ANGIOGENESIS+0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- COMPLEMENT+0.470
- KRAS_SIGNALING_UP+0.470
- COAGULATION+0.460
- IL2_STAT5_SIGNALING+0.440
Top 10 suppressed
- MYC_TARGETS_V1-0.610
- MYC_TARGETS_V2-0.570
- PROTEIN_SECRETION-0.560
- E2F_TARGETS-0.530
- UNFOLDED_PROTEIN_RESPONSE-0.520
- G2M_CHECKPOINT-0.510
- MTORC1_SIGNALING-0.390
- OXIDATIVE_PHOSPHORYLATION-0.390
- DNA_REPAIR-0.370
- MITOTIC_SPINDLE-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-GM-A4E0-01A-12R-A266-07 | — | A | 0.948 |
| 2 | C3L-02164 | — | cohortMD2 | 0.946 |
| 3 | TCGA-99-8028-01A-11R-2241-07 | — | cohortMD2 | 0.940 |
| 4 | TCGA-XX-A89A-01A-11R-A36F-07 | — | A | 0.940 |
| 5 | TCGA-A2-A0CO-01A-13R-A22K-07 | — | A | 0.936 |
| 6 | TCGA-LD-A9QF-01A-32R-A41B-07 | — | D | 0.934 |
| 7 | TCGA-XX-A899-01A-11R-A36F-07 | — | A | 0.932 |
| 8 | TCGA-A2-A0EN-01A-13R-A084-07 | — | A | 0.932 |
| 9 | TCGA-77-A5FZ-01A-31R-A27Q-07 | — | cohortMD2 | 0.932 |
| 10 | 20120155.TNBC | — | D | 0.931 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.620 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.580 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.580 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| COMPLEMENT | 0.470 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.470 | Inavolisib | — uncovered |
| COAGULATION | 0.460 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.440 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| HYPOXIA | 0.320 | Idelalisib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.220 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |